Navigation Links
Alfacell Reports Fiscal Fourth Quarter and Full Year 2008 Financial Results
Date:10/14/2008

SOMERSET, N.J., Oct. 14 /PRNewswire-FirstCall/ -- Alfacell Corporation (Nasdaq: ACEL) today reported its financial results for the fourth quarter and fiscal year ended July 31, 2008.

The company recorded a net loss of approximately $2.9 million, or $0.06 per basic and diluted common share, for the fourth fiscal quarter ended July 31, compared to a net loss of approximately $2.4 million, or $0.05 per basic and diluted common share, for the fourth quarter of fiscal 2007. Research and development expenses increased by approximately $0.9 million during the fourth quarter of fiscal 2008 as compared to the same quarter a year ago primarily due to expenses incurred related to the company's preparations for the completion of its ONCONASE(R) rolling New Drug Application (NDA) submission. Decreased general and administrative expenses of approximately $0.5 million for the fourth quarter of fiscal 2008 were primarily the result of reduced stock based compensation expenses.

Net loss for the fiscal year ended July 31, 2008 of approximately $12.3 million, or $0.26 per basic and diluted common share, represents an increase of approximately $3.5 million, compared to the $8.8 million net loss, or $0.19 per basic and diluted common share, for fiscal 2007.

Cash and Liquidity

As of July 31, 2008, the company had cash and cash equivalents of approximately $4.7 million, a decrease of approximately $3.1 million, compared to cash and cash equivalents of approximately $7.8 million on April 30, 2008. The company has received notification that it continues to qualify for the sale of its state tax loss carryforwards in New Jersey and is awaiting additional information on the proceeds it can expect to receive from this sale in late 2008
'/>"/>

SOURCE Alfacell Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Paper in Cell Cycle Reports Alfacells ONCONASE(R) Targets siRNA
2. Alfacell Hires Advisors to Advance Strategic Alternatives
3. Alfacell Receives NASDAQ Delisting Letter
4. Alfacell Receives NASDAQ Non-Compliance Notification
5. Alfacell Reports Financial Results for Third Quarter of Fiscal 2008
6. Alfacell Announces Retirement of Chief Executive Officer
7. Alfacell Reports Financial Results for Second Quarter of Fiscal 2008
8. Alfacell to Host Fiscal Second Quarter 2008 Financial Results Conference Call and Webcast
9. Alfacell Announces ONCONASE(R) Purchase and Supply Agreement with Scientific Protein Laboratories
10. Alfacell to Host Webinar on RNA Interference-Like Mechanics of RNase Therapeutics on Nov. 29
11. Alfacell to Host Fiscal Fourth Quarter and Year-End 2007 Financial Results Conference Call and Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/31/2015)... 31, 2015 CytoSorbents Corporation (NASDAQ CM: ... purification to treat critically-ill and cardiac surgery patients ... and reports financial results for the fiscal year ... CytoSorb® product revenues were a record $3.1M, an ... CytoSorb® revenues of $0.8M Highlights for the Year ...
(Date:3/31/2015)... (PRWEB) March 31, 2015 Eastern ... schools for online bachelor’s of criminal justice degree ... connecting people to inspiring ideas and high quality ... e-mail to the University. We are confident that ... , This is the site’s first “Students ...
(Date:3/31/2015)... -- Sonoa Health, a health tech startup based in ... consumer health portal, Health&, which brings together data from ... Today, the Company appointed respected investment banker ... to the table more than 18-years experience in investment ... with the biggest names in Silicon Valley in the ...
(Date:3/31/2015)... , March 31, 2015  The Myeloma Crowd ... the selection of ten proposals that will now ... the first patient-led, scientifically validated funding initiative uncovering ... Stage 2 of the MCRI included preliminary vetting ... of a large number of innovative projects focusing ...
Breaking Biology Technology:CytoSorbents Reports Record 2014 Revenue 2CytoSorbents Reports Record 2014 Revenue 3CytoSorbents Reports Record 2014 Revenue 4CytoSorbents Reports Record 2014 Revenue 5CytoSorbents Reports Record 2014 Revenue 6CytoSorbents Reports Record 2014 Revenue 7CytoSorbents Reports Record 2014 Revenue 8CytoSorbents Reports Record 2014 Revenue 9CytoSorbents Reports Record 2014 Revenue 10CytoSorbents Reports Record 2014 Revenue 11EKU Ranked in Top 50 Among Online Criminal Justice Degrees 2Investment Banker Appointed CEO of Australian Health Tech Start-Up 2Investment Banker Appointed CEO of Australian Health Tech Start-Up 3Myeloma Crowd Research Initiative Selects 10 High-Risk Multiple Myeloma Proposals For Further Review 2
... operating income of $856,000, IRVINE, Calif., March ... developer of surgical products,and accessories used in angina-relieving ... and fiscal year ended December 31,2007., Sales ... a 24% decrease,from the prior year fourth quarter ...
... FRANCISCO, March 25 Medivation, Inc.,(Nasdaq: MDVN ... Bronson, Ph.D.,to vice president, regulatory and quality, Mohammad ... Mordenti, Ph.D., to vice,president, translational medicine., "As ... product candidate, we are,strengthening the team to lead ...
... MARINO, Calif., March 25 Epeius Biotechnologies,Corporation ... No. 7,347,998 for,Targeted Gene Delivery in vivo. ... the platform of highly advanced,biotechnologies embodied in ... by simple intravenous infusion, the Epeius,tumor-targeted gene ...
Cached Biology Technology:Cardiogenesis Reports Fourth Quarter and Full Year 2007 Results 2Cardiogenesis Reports Fourth Quarter and Full Year 2007 Results 3Cardiogenesis Reports Fourth Quarter and Full Year 2007 Results 4Cardiogenesis Reports Fourth Quarter and Full Year 2007 Results 5Cardiogenesis Reports Fourth Quarter and Full Year 2007 Results 6Cardiogenesis Reports Fourth Quarter and Full Year 2007 Results 7Medivation Announces Senior Management Promotions 2Medivation Announces Senior Management Promotions 3Epeius Biotechnologies Awarded U.S. Patent for Targeted Injectable Gene Delivery In Vivo 2
(Date:3/23/2015)... Mass , March 23, 2015 SoundView Technology ... of NXT-ID,s (NASDAQ: NXTD ) Wocket smart wallet. SoundView was ... user feedback on their experience with the Wocket in multiple ... at CVS, Whole Foods and other retailers, making both debit ... Kris Tuttle also says, "If the company meets their ...
(Date:3/23/2015)... ANGELES , March 23, 2015  In the ... Federal fraud case conviction losses. This figure accounts for ... which, according to The Nilson Report, exceeds $11 billion ... investigative tool after a crime has occurred. Investor ... and polygraph expert Joe Paolella partnered to ...
(Date:3/20/2015)... , Mar. 20, 2015 Research and ... the addition of the "India Sensors Market ... offering. The sensor market is projected ... 2020 Consumer electronics, automotive, industrial and ... sensors in the country. In addition, adoption of ...
Breaking Biology News(10 mins):Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 2Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 3Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 4Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 2India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 3
... recently discovered form of the protein that triggers blood ... of metastatic pancreatic cancer and primary breast cancer, according ... published online ahead of print in the International ... Proceedings of the National Academy of Sciences ). ...
... and hope to be a father, here,s another reason ... your waistline or metabolic disorders. That,s because scientists have ... did not show any signs of diabetes, passed this ... Sons don,t entirely dodge this genetic bullet eitherboth sons ...
... and the National Institutes of Health have obtained ground-breaking new ... play a role in the development of cancer cells. The ... and have just been published in Journal of Biological ... of proteases to force their way into the body., In ...
Cached Biology News:Metastatic pancreatic, primary breast cancer have common growth mechanisms, study suggests 2Obese dads pass on predisposition to obesity and metabolic disorders to their kids 2Molecular discovery puts cancer treatment in a new perspective 2Molecular discovery puts cancer treatment in a new perspective 3
... Brownlee Precision Model 440 incorporates four channels ... a friendly easy-to-use instrument. Each channel consists ... 8-pole Bessel lowpass filter, a highpass filter, ... controls. A control knob sets the amplifier ...
... The H2OBIT™ is a fully licensed, high ... simultaneous processing of up to 24 microplates. This ... 384-well plates. A robotic arm rapidly ... baths resulting in temperature ramping times that are ...
... The Brownlee Precision Model 410 is a four-channel ... to amplify small signals from sources which may ... noise. Each channel consists of a high gain/low ... lowpass filter, and an output offset control. A ...
... Pro-OpioMelanoCortin (POMC) has long been a ... precursor to a multiplicity of biologically-active ... -endorphin, Alpha-Melanocyte Stimulating Hormone (a-MSH) and ... well-conserved molecule, being found in most ...
Biology Products: